Mesoestetic Pharma Group S.L.
10
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
10%
1 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Evaluation of the Safety and Performance Characteristics of Mesofiller Aox for the Correction of Mild and Moderate Facial Wrinkles.
Role: lead
Efficacy and Performance Evaluation of mGlobal L+AS 20 mg/ml Hyaluronic Acid, for the Correction of Light to Moderate Wrinkles and Folds
Role: lead
Evaluation of the Safety and Performance Characteristics of Mesofiller Mesotox for the Correction of Wrinkles and Rehydration of the Face.
Role: lead
Efficacy and Performance Evaluation of mIntense L+AS 25 mg/ml Hyaluronic Acid for the Correction of Moderate to Deep Wrinkles and Folds
Role: lead
Clinical Investigation to Assess Safety and Performance of Dermal Filler of Hyaluronic Acid
Role: lead
Evaluation of the Efficacy and Safety of the Dermal Filler for Female Intimate Area Hydration and Atrophy of the Vagina.
Role: lead
Evaluation of the Efficacy and Safety of the Dermal Filler for Augmentation of Labia Majora.
Role: lead
Assessment of the Safety and Efficacy of the Dermal Filler "mARG-01-17" in Facial Rejuvenation Therapy
Role: lead
Pilot Trial to Assess the Performance and Tolerance of mRDX-02-17 Dermal Filler in the Facial Rejuvenation
Role: lead
Efficacy and Safety of a 4% Hydroquinone Cream for the Treatment of Melasma
Role: lead
All 10 trials loaded